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Risk factors for Clostridium difficile infections – 
an overview of the evidence base and challenges 
in data synthesis
Background Recognition of a broad spectrum of disease and develop-
ment of Clostridium difficile infection (CDI) and recurrent CDI (rCDI) 
in populations previously considered to be at low risk has renewed at-
tention on differences in the risk profile of patients. In the absence of 
primary prevention for CDI and limited treatment options, it is impor-
tant to achieve a deep understanding of the multiple factors that influ-
ence the risk of developing CDI and rCDI.
Methods We conducted a review of systematic reviews and meta–anal-
yses on risk factors for CDI and rCDI published between 1990 and 
October 2016.
Results 22 systematic reviews assessing risk factors for CDI (n = 19) 
and rCDI (n = 6) were included. Meta–analyses were conducted in 17 
of the systematic reviews. Over 40 risk factors have been associated 
with CDI and rCDI and can be classified into three categories: phar-
macological risk factors, host–related risk factors, and clinical charac-
teristics or interventions. Most systematic reviews and meta–analyses 
have focused on antibiotic use (n = 8 for CDI, 3 for rCDI), proton pump 
inhibitors (n = 8 for CDI, 4 for rCDI), and histamine 2 receptor antag-
onists (n = 4 for CDI) and chronic kidney disease (n = 4 for rCDI). How-
ever, other risk factors have been assessed. We discuss the state of the 
evidence, methods, and challenges for data synthesis.
Conclusion Several studies, synthesized in different systematic review, 
provide valuable insights into the role of different risk factors for CDI. 
Meta–analytic evidence of association has been reported for factors 
such as antibiotics, gastric acid suppressants, non–selective NSAID, 
and some co–morbidities. However, despite statistical significance, is-
sues of high heterogeneity, bias and confounding remain to be ad-
dressed effectively to improve overall risk estimates. Large, prospective 
primary studies on risk factors for CDI with standardised case defini-
tions and stratified analyses are required to develop more accurate and 
robust estimates of risk effects that can inform targeted–CDI clinical 
management procedures, prevention, and research.
Electronic supplementary material: 
The online version of this article contains supplementary material.
Clostridium difficile infection (CDI) is considered an urgent public health 
threat [1]. In 2011, a total of 453 000 incident CDI cases were estimated 
in the USA alone, with an additional 83 000 first recurrences (rCDI) and 
29 300 deaths [2]. In Europe, where rates of CDI among inpatients range 
from 0.7 to 28.7 per 10 000 patient bed–days, at least 40 000 CDI cases are 
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thought to be missed every year through lack of clinical suspicion and inadequate laboratory testing [3]. 
Endemic CDI and outbreaks have been reported from all world regions, including Asia, Western Pacific, 
Latin America, and Africa [4–13]. By increasing the length of hospital stay, in addition to the extra costs 
of diagnosis, treatment, and in some cases surgery or fatal outcomes, CDI places a large economic burden 
on health care finances and patients [14]. It is estimated that the total annual hospital management of 
CDI infection in the US alone is US$ 6.3 billion [15].
Recognition of a broad spectrum of disease and development of CDI in populations previously consid-
ered to be at low risk has renewed attention on differences in the risk profile of patients. A substantial 
proportion of CDI cases, between 20 to 30%, are now considered to be community–associated [16] and 
at least 25% of incident CDI cases will suffer at least a relapse or first recurrence (rCDI) within 30 days 
of treatment [17]. In the absence of primary prevention for CDI and limited treatment options, it is im-
portant to achieve a deep understanding of the multiple factors that influence the risk of developing CDI 
and rCDI. Commonly reported risk factors include advanced age, co–morbidities, use of antibiotics, pro-
ton pump inhibitors (PPIs), histamine–2 receptor antagonists (H2RA) and exposure to health care set-
tings. Other risk factors have also implicated include obesity [18–20], non–steroidal anti–inflammatory 
drugs (NSAID) [21,22], vitamin D [23], and the role of host genetics in acquiring CDI [24]. We exam-
ined systematic reviews and meta–analyses on risk factors for CDI to provide an overview of the state of 
the evidence and discuss some of the challenges for epidemiological data synthesis for CDI and rCDI.
METHODS
We searched the following databases: MEDLINE and EMBASE (Ovid); CINAHL; Cochrane database; and 
Global Health Library. Our eligibility criteria are detailed in Box 1 and search terms used for each data-
base are available in Table S1 in Online Supplementary Document.
RESULTS
We found that multiple systematic reviews had assessed the same risk factors. Furthermore, meta–analy-
ses provided different estimates of association for similar factors. Thus, we focus our review on the con-
clusions of the publications rather than numerical risk estimates. Table 1 provides a summary of the risk 
factors identified through our review, classified into three main groups. All, but one, of the primary stud-
ies in these systematic reviews were conducted in industrialised countries of North America, Europe, and 
Western Pacific region.
Pharmacological agents
Antibiotics
CDI has traditionally been regarded as a complication of antimicrobial therapy, particularly broad–spec-
trum antibiotics that can disrupt the gut flora in hospitalised patients [40]. Several systematic reviews, 
with or without meta–analyses, have evaluated the role of different antibiotics by class or generation. The 
first meta–analysis to quantify the risk, published in 1998 [25], found a strong and statistically significant 
Box 1. Inclusion and exclusion criteria
Inclusion:
•  Systematic reviews with or without meta–analysis examining risk factors for CDI or recurrent episodes in all 
age groups
• Published between 1990 to October 2016
•  Published in English
Exclusion:
•  Systematic reviews and meta–analyses that focused on mortality, health care costs or treatment, or coloniza-
tion by C. difficile
• Narrative reviews or those with methods not clearly described
•  Randomised controlled trials (RCTs); Observational studies (cohort and case control studies); laboratory ex-
periments and in–vitro studies
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Risk factors for C. difficile infections
association between antibiotic use and CDI; the risk of CDI was found to be 6 times higher on average 
compared to individuals not on antimicrobial therapy. Clindamycin, cephalosporins, and fluoroquino-
lones were and remain associated with the greatest risk of CDI [21,26–28]. Continued use of CDI high–
risk antibiotics during follow–up has also been associated with a statistically significant increase in the 
risk of rCDI [33]. Consequently, antibiotic stewardship programmes are widely recommended for the 
prevention of CDI and there is substantial interest in recommendations for which antibiotics should be 
targeted [41].
As several antibiotics have been associated with CDI and rCDI, it is important to consider a number of 
issues before targeting specific antibiotics over others as means of prevention. Meta–analyses have found 
substantial heterogeneity in the studies for most antibiotic classes and generations, limiting the ability to 
Table 1. Examples of systematic reviews and meta–analyses on risk factors for Clostridium difficile infection (CDI)
Risk factoR cDi RecuRRent cDi
Number of systematic reviews [ref]
Pharmacological risk factors:
Any use of antibiotics (broad and specific) 8 [21,25-31] 3 [32-34]
Any use of proton pump inhibitors 8 [21,25-31] 4 [32,33,35,36]
Any use of histamine 2 receptor antagonists 4 [21,36-38]
Anti–ulcer medications (not specific) 2 [25,37] 1 [34]
Non–steroidal anti–inflammatory drug 2 [21,22]
Aspirin 1 [21]
Corticosteroids 1 [21]
Use of opiate during the last episode of CDI 1 [32]
Host–related risk factors:
Age: ≥65 years 2 [21,31] 3 [32-34]
Age: additional year or decade 1 [25] 2 [32,33]
Chronic kidney disease 2 [21,39] 4 [32-34,39]
Diabetes mellitus 1 [21] 1 [32]
Lymphoma or leukaemia 1 [21,31]
Solid cancer or malignancy 1 [21,31]
Severity of co–morbidity 1 [25]
Inflammatory bowel disease 1 [21]
Congestive heart disease 1 [21]
Chronic obstructive pulmonary disease 1 [21]
Peptic ulcer 1 [21]
Diverticular disease 1 [21]
Gastroesophageal reflux disease 1 [21]
Chronic obstructive pulmonary disease 1 [21]
Low mean concentration of 25 hydroxyvitamin D 1 [23]
Female sex 1 [34]
Previous diagnosis of CDI 1 [32]
Additional points Charlson scale 1 [32]
Clinical interventions or characteristics:
Duration of hospitalization 1 [25] 1 [32]
Nasogastric tube feeding 2 [25,31] 1 [33]
Stay in intensive treatment unit 1 [25]
Non–surgical GI procedure 1 [25]
Vomiting 1 [32]
Previous GI hospitalization 1 [32]
History of surgery 1 [32]
Leucocytes >20 cells/hpf 1 [32]
High faecal interleukin–8 1 [32]
Previous gastrointestinal procedure 1 [32]
Low day–3 IgM anti–toxin A 1 [32]
Serum albumin <2.5g/dL 1 [32]
Hyponatremia 1 [32]
Lymphopenia 1 [32]
Colonization with vancomycin–resistant enterococci 1 [32]
GI – gastrointestinal, hpf – high power field
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draw conclusions about the risk estimates for specific drugs. Furthermore, there are difficulties in ad-
dressing the sources of heterogeneity, as these are wide–ranging: significant pharmacological differences 
even within generations [41], potential antibiotic selection pressure for particular C. difficile strains, such 
as fluoroquinolones and NAP1/B1/027 [41], increased use of other antimicrobials with unknown effect 
on CDI [42], and differences in local or national guidelines for antibiotic prescribing. Since much of the 
literature on risk factors for CDI is based on observational studies, the risk estimates from meta–analyses 
are both confounded as well as biased.
Interesting findings have emerged from recent meta–analytical approaches estimating the association be-
tween antibiotics and CDI in different settings. Differences in strengths of association have been found 
once data for antibiotics are disaggregated by setting or world region. In the hospital setting, as compared 
to non–diarrheal controls, clindamycin, cephalosporins, carbapenems, fluoroquinolones and trime-
thoprim/sulphonamides were associated with at least a 2 times an increased risk of CDI, although confi-
dence intervals for pooled estimates among antibiotic classes overlapped [28]. In the community, these 
antibiotics were associated with a higher risk for CDI – between 8 to 20 times the risk for clindamycin 
[21,26,27] and 3 to 5 times for cephalosporins and quinolones, but definition of controls groups varied 
[21]. Macrolides were associated with a 2– to 3–fold higher and statistically significant risk for commu-
nity–associated CDI but not for hospital–associated CDI [21,26,27]. Non–significant risks have been re-
ported for tetracycline in either setting [21,26–28]. Aminoglycosides have not been found to be signifi-
cantly associated with CDI in the health care setting [28], but no evidence were available for 
community–associated CDI. A greater strength of association between exposure to antibiotics and com-
munity–associated CDI in the USA as compared to Europe [21]. Furthermore, stronger associations ob-
served between specific antibiotics and community–associated CDI could be due to less confounding ef-
fects inherent to studies within hospitals [43]. Limitations notwithstanding, differing estimates of risk for 
similar antibiotics for hospital or community–associated CDI underscores the importance of a robust ev-
idence–base for the development of relevant antimicrobial prescribing practices for CDI.
Gastric acid suppressors
Acid related upper–gastrointestinal disorders including peptic ulcer disease and gastro–esophageal reflux 
disease are now mainly treated with PPIs and H2RAs [37,44,45]. Although PPIs are generally thought to 
have a good safety profile, systematic reviews and meta–analyses suggest otherwise, with an overall sig-
nificant association between the use of PPIs and CDI [21,35–37,44–47] and rCDI [32,33,35,36]. A sta-
tistically significant association between the use of H2RAs and CDI has also been reported in meta–anal-
yses [21,36–38]. Limited evidence on the risk posed by the continuous use of H2RAs on rCDI, or on the 
relative risk of H2RAs vs PPIs for CDI prevents conclusions from being drawn [36,37]. As for much of 
the evidence on risk factors for CDI, results are largely from observational studies and, thus, despite the 
extent of the literature and the plausibility of these findings, confounders such as polypharmacy and co-
morbidities may still play a role and causality cannot be established. It is important to note that varying 
strengths of association have been reported in primary studies, reinforcing the need for careful interpre-
tation of meta–estimates. For instance, the association between PPIs and CDI remains significant when 
stratified by antibiotic use among CDI cases (>80% vs £80%) [46] and by study design (case–control 
studies vs cohort studies) [36,44,46]. However, heterogeneity (defined as >50% or P < 0.005) was ob-
served in all subgroup analyses [36,37,44,46], even when unadjusted vs adjusted risk estimates from pri-
mary studies were analyzed separately [36]. Similar to antibiotics, regional prescribing practices have the 
potential to impact meta–estimates. A greater strength of association between exposure to PPIs and com-
munity–associated CDI was observed in studies from Europe as compared to the USA.
Other drugs
Discrepancies have been reported for the use of NSAIDs as a factor influencing the risk of CDI. The use 
of aspirin was not significantly associated with CDI in the community but corticosteroids were, as report-
ed in one meta–analysis [21]. However, the use of non–selective NSAID (excluding COX–2 inhibitors) 
was associated with CDI [22]. Understanding the differences between risk estimates and CDI case defini-
tion by setting are extremely important for the accurate assessment of the relevance of study findings.
Host–related risk factors
Age
The well–known role of increased age as a risk factor for incident CDI and rCDI has largely been assessed 
using two criteria: per additional year or decade, or age ≥65 years [31–34]. The incidence of C. difficile 
hospitalisations among patients ≥65 years increased most sharply among this age group in Finland in the 
Eze et al.
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early 2000s [48]. In 2011, rates of CDI were 4–fold higher than among adults aged 45–65 and 13–fold 
higher as compared to those aged 18–44 in the USA [2]. Furthermore, older age has been associated with 
an increased risk of CDI with the virulent strain BI/NAP1/027 [31] as well as rCDI [33,34].
Age is a common confounder for which estimates are adjusted in primary studies assessing risk factors 
for CDI [27,28]. There is great value in having age–stratified estimates of risk, and these have been pro-
vided in several meta–analyses. For instance, the risk of CDI in the community associated with antimi-
crobial exposure was approximately 2–fold higher among older adults (≥65 years of age) as compared 
with children and younger adults [21]. Furthermore, the risk estimate for the use of NSAIDs was signif-
icant based on studies with study populations with mean age of 50 or older, but not significant among 
those with younger age [22]. Similarly, the risk posed by PPI was more pronounced among adults than 
in the elderly (≥65 years of age) or children [21]. Analytical approaches to elucidate how the risk of CDI 
differs among populations are important to better differentiate among populations at risk and the devel-
opment of targeted recommendations.
Comorbidities
The association between CDI and selected comorbidities has also been explored systematically. A system-
atic review highlighted an increased risk of community–associated CDI cases among patients with inflam-
matory bowel disease, diabetes, leukemia or lymphoma, renal failure, and solid cancer [21], among a 
wide range of other comorbidities that have been implicated. Although other study populations are like-
ly to be susceptible, such meta–analytical approaches add to the evidence base by pointing toward spe-
cific conditions that may require further attention in the clinical setting and in research studies.
Although there is evidence that lower 25–hydroxyvitamin D (25(OH)D) status increases susceptibility to 
infectious diseases, the evidence is insufficient to establish an association with CDI. A recent assessment 
of studies evaluating the role of low 25(OH)D and CDI suggested a significant association with rCDI. 
However, considering that these were based on three studies only, no differences can be observed between 
outcomes of CDI in hospital or community settings.
Clinical characteristics and interventions
The association between CDI and exposure to health care settings is well recognized. However, the risk 
posed by different interventions remains poorly understood as the available evidence is potentially con-
founded by other in–patient associated characteristics. A longer hospital stay is strongly associated with 
exposure to C. difficile spores and the likelihood of colonization [25,49]. However, results regarding the 
length of stay as a determinant for CDI from primary studies have not been consistent. For instance, pa-
tients who developed CDI were hospitalised 2–4 times longer [50], while no differences in hospital stay 
between CDI patients and non–CDI patients have also been observed [51]. Similarly, one study showed 
a strong association between CDI and length of hospital stay and ICU stay in univariate analysis but a 
weak association with a wider 95% confidence interval (CI) was reported in the multivariate analysis [52]. 
The risk of CDI has been shown to be greater in individuals undergoing invasive procedures, such as ab-
dominal surgery, nasogastric tube placement, mechanical ventilation, all of which are associated with pro-
longed hospitalization [53,54]. A meta–estimate for the association between CDI or rCDI was not identi-
fied for most of the clinical interventions in systematic reviews (Table 1). The risk of nasogastric tube 
feeding and rCDI was estimated in one meta–analysis from data in 3 primary studies and found to be not 
significantly associated [33].
Despite difficulties in developing a rigid clinical prediction rule for CDI or rCDI, prognostic factors that 
correlate with poor outcome have been differentiated and informed guidance [55]. Key factors include 
age, treatment with systemic antibiotics, leucocyte count, albumin, and temperature at time of diagnosis. 
Furthermore, 5 types of CDI patient groups have been differentiated, based on severity of disease. This 
classification is important for clinical management and for research.
DISCUSSION
Implications of challenges in data synthesis for prevention of CDI and further 
research
There are two major public health goals in relation to CDI prevention. First, it is important to reduce the 
total number of cases. Second, it is essential to prevent a poor or fatal outcome of those with severe pre-
Risk factors for C. difficile infections
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sentation. The availability of new therapeutic and preventive measures such as immunoglobulin, faecal 
transplant, and vaccines could help reduce CDI morbidity, mortality and costs. For these strategies to be 
effective and properly targeted to high–risk patients, evidence on risk factors is necessary.
Varying definitions and reporting levels in primary studies are common issues that challenge or preclude 
meta–analytical synthesis of the evidence, particularly, the case definition of CDI. In available studies, cri-
teria for the definition can range from hospitalisation records of C. difficile, on its own or combined with 
prescription of oral vancomycin, clinical diarrhea, to laboratory confirmation of CDI, with or without 
presence of pseudomembranous colitis. An essential first step in the assessment of risk factors for CDI is 
that future studies adhere to recommended surveillance case definitions for CDI [56] and that efforts are 
made to support case ascertainment with adequate diagnostic tests [3]. This will not only minimise mis-
classification bias of asymptomatic patients but also allow for further analytical differentiation of incident 
CDI and recurrent cases occurring in the community or in the hospital setting. Early detection of severe 
cases and targeted management, such as early surgical consultation with CDI patients, is essential to pre-
vent poor or fatal outcomes.
CDI data collated by different setting of acquisition have the potential to enable targeted advances in the 
development of preventive and treatment options. For instance, both probiotics and fidaxomicin have 
been proposed for the prevention of rCDI among patients at “high risk” of recurrence. Similarly, faecal 
transplantation methods are also now available for treating rCDI [57]. Better quality data are required to 
make official recommendations on the use of probiotics [58] and the high cost of fidaxomicin poses re-
strictions for a cost–effective use if those at high risk cannot be correctly identified [59]. Prevention through 
vaccination is a promising perspective that could tackle CDI primary infections [60]. More evidence is 
also required to develop prescribing recommendations of pharmacological agents (with the potential to 
disrupt the gut flora, such as PPIs and H2RA) in the community that would result in a reduction of the 
risk of CDI.
Another common limitation in the assessment of risk factors for CDI is that data are from observational 
studies. Given that this will likely remain unchanged, special attention and consensus on potential con-
founders and selection of comparator groups are needed in the study design or analysis stages. Evidence–
base guidance requires data on risk factors to identify patient characteristics that correlate positively with 
the severity of disease. Bias is likely to be introduced if study populations are not representative of all po-
tential cases by restricting the pool of CDI cases to those patients with recent antibiotic exposure or con-
trols to those with antibiotic–associated or hospital–acquired, toxin–negative diarrhea.
Age, sex, concomitant medication, and comorbidities are often common confounders adjusted for in pri-
mary analyses [33], but data on risk factors for CDI requires further considerations. It is important that 
parameters on the duration and dosage of drugs associated with a risk of CDI, including antibiotics, PPIs, 
H2RA, and even NSAIDs, are reported clearly to enable subgroup analyses and their consideration in 
multivariate analyses in primary studies. Studies and meta–analyses have not been able to account for 
these factors adequately, thus more research is needed. Features of research that would strengthen the 
evidence base include matched control groups (particularly by age, gender, and location) as well as an 
examination of duration and number of drug doses (antibiotics and other drugs). A full assessment of 
adherence to drug treatments, particularly in the community, is difficult to achieve and its effects mini-
mised as much as possible in both the study design and analysis (eg, using dispensed drugs data rather 
than prescribed). The importance of a nuanced approach to better understand the role of antibiotics and 
development of CDI was demonstrated in a recent study, which found a dose–dependent association of 
cumulative exposure (in terms of doses) and temporal effect (within 6 months prior to diagnosis) of an-
tibiotics use and community–associated CDI [61].
Finally, the vast majority of primary studies aimed at estimating risk factors influencing CDI are conduct-
ed in industrialised countries, where prevention is currently focused on judicious antibiotic use. The bur-
den of CDI in developing countries where overuse of antibiotic is also prevalent [62] remains poorly de-
scribed and the capacity to detect and report its incidence needs is limited [63]. This represents a large 
knowledge gap in CDI epidemiology. The paucity of evidence on CDI incidence and strength of associa-
tion of different risk factors is worrisome in view of the potential wide–spread of hyper–virulent strains 
of C. difficile as seen for BI/NAP1/027 [16]. Additional, well–designed studies and standardised surveil-
lance methods [64] that integrate clinical and epidemiological data are required in these settings to assess 
the role of multiple in–hospital and community factors –which may differ from high–resource set-
tings − that can have an impact on CDI or rCDI.
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CONCLUSION
Several studies provide valuable insights into the role of different risk factors for CDI and meta–analytic 
evidence of association has been reported for putative factors. However, despite statistical significance, 
issues of high heterogeneity, bias and confounding remain to be addressed effectively to improve overall 
risk estimates. Further, given the evolving epidemiology of C. difficile world–wide, there is a particular 
interest in achieving a better understanding of the role of the various factors leading to CDI in the hospi-
tal vs the community setting. Thus, there would be great value in large, prospective primary studies on 
risk factors for CDI with standardised case definitions and stratified analyses to develop more accurate 
estimates of risk effects that can inform targeted–CDI clinical management procedures, prevention, and 
research.
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